VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)

Ana Oaknin ,L Fariñas Madrid,U.F.F De Giorgi,L Gladieff,Domenica Lorusso ,Munetaka Takekuma ,Linn Woelber ,M.j Rubio Pérez ,Kristina Lindemann ,Jerónimo Martínez-García ,A Ortiz ,Satoshi Yamaguchi ,Linda R Duska ,Guillermo Villacampa ,Véronique D’hondt ,Antoine Angelergues ,Alexandra Léary ,Shin Nishio ,Nicoletta Colombo ,Leslie M Randall

doi:10.1016/j.annonc.2023.10.694

VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)

Ana Oaknin , L Fariñas Madrid + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2023.10.694

Copy DOI

Journal: Annals of Oncology	Publication Date: Nov 6, 2023
Citations: 5

Affiliation: Spanish Ovarian Cancer Research Group, Vall d'Hebron Hospital Universitari, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituti di Ricovero e Cura a Carattere Scientifico, Institut Claudius Regaud, Agostino Gemelli University Polyclinic, Shizuoka Cancer Center, University Medical Center Hamburg-Eppendorf, Universität Hamburg, Hospital Universitario Reina Sofía, University of Oslo, Oslo University Hospital, Hospital Universitario Virgen de la Arrixaca, Hospital Regional Universitario de Málaga, Hyogo Prefectural Cancer Center, University of Virginia, CIBBIM-Nanomedicine, Institute of Cancer Research of Montpellier, Groupe Hospitalier Diaconesses Croix Saint-Simon, Institut Gustave Roussy, Kurume University, European Institute of Oncology, University of Milan, University of Miami Health System

#Recurrent Cervical Cancer #Platinum Doublet + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.